AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$CSTL

MAETZOLD DEREK J sold $305K of CSTL

MAETZOLD DEREK J (Pres. & Chief Exec. Officer) sold 8,580 shares of CASTLE BIOSCIENCES INC (CSTL) at $35.57 ($0.31M total) on 2026-10-05 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · MAETZOLD DEREK J
Published Oct 7, 2026, 8:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 8:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CSTL
Bearish
medium confidence
Mentioned
$CSTL
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CSTLBearishLow
01

Why it matters

The disclosed sale could trigger short‑term selling pressure, but the modest amount limits material impact.

02

Market read

A fresh insider sale by the CEO provides a new data point for traders, though its small size suggests limited market impact.

03

What to watch

The 10b5‑1 plan indicates the sale was pre‑scheduled, reducing informational value.

Relevance 3/10Novelty 3/10Timing: today

Background

Form 4 filings disclose insider transactions; a 10b5‑1 plan sale by a CEO is a standard compliance disclosure.

Company-level read

Ticker impact

$CSTLBearishMedium confidence
Context

CEO/Derek Maetzold sold 8,580 shares for $305,156, reducing his stake to 21,064 shares.

Expected impact

likely pressure as the market prices in the insider sell

Evidence & confidence

A 10b5‑1 sale by the chief executive, though modest in size, is a fresh primary filing that can prompt short‑term downside.

Market effects

Sector

Minimal impact on the biotech sector; insider sales are common and unlikely to shift sector sentiment.

Regional

Limited to U.S. investors tracking Castle Biosciences; no broader regional effect.

Global

Negligible on a global scale.

Counterpoint

What could challenge this read

The sale may be purely portfolio rebalancing under a pre‑arranged plan, not a negative signal.

Key entities

  • Company
    Castle Biosciences Inc.

    Biotech firm listed on NASDAQ under ticker CSTL.

  • Person
    Derek J. Maetzold

    President & Chief Executive Officer of Castle Biosciences.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CSTL insider trading history →

Related articles

$CSTLMed

DecisionDx®-Melanoma Data at SDPA and Dermato-Onco2026 Support the Test's Ability to Refine Risk Assessment Beyond AJCC Staging

Castle Biosciences presented data on DecisionDx-Melanoma at SDPA and Dermato-Onco2026, showing the test can identify higher-risk patients with thin melanomas and provide individualized five-year recurrence-risk estimates. The studies suggest the test refines risk assessment beyond AJCC staging, aiding personalized care. According to the company, the test has been ordered over 260,000 times and is supported by extensive research.

prnewswire.com
$CSTLMed

Castle Bio (CSTL) Q3 2026 Earnings Call Transcript

Castle Bio (CSTL) reported Q3 2026 revenue of $102.9M, up 24% YoY, driven by 47% growth in TissueCypher test volume. Net cash from operations was $19.7M, with $278M in cash and equivalents. The company raised full-year revenue guidance to $385M-$395M, up from $365M-$375M. DecisionDx-Melanoma saw 5% YoY growth, while TissueCypher is expected to grow 50%-52% for the year.

finance.yahoo.com
$CSTLHigh

Castle Biosciences Reports Third Quarter 2026 Results

CASTLE BIOSCIENCES INC (CSTL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Castle Biosciences Reports Third Quarter 2026 Results Delivered Q3 2026 revenue of $102.9 million, an increase of 24% over Q3 2025 TissueCypher ® test report volume increased 47% over Q3 2025 Raising full-year 2026 revenue guidance to $385-395 million from $365-375 m

SEC EDGAR 8-K
$CSTLHighAI 8/10

Castle Biosciences Reports Third Quarter 2026 Results

Castle Biosciences reported Q3 2026 revenue of $102.9M, up 24% YoY. TissueCypher test volume rose 47% YoY. The company raised full-year 2026 revenue guidance to $385-395M. Q3 net loss was $4.1M, with Adjusted EBITDA of $12.7M. The company presented new data on its DecisionDx-Melanoma test at EADV Congress 2026.

prnewswire.com
$CSTLMed

Late-Breaking EADV 2026 Data Support Use of DecisionDx®-Melanoma in SLNB Decision-Making and Risk-Aligned Post Surgical Management

Castle Biosciences presented data at EADV 2026 showing DecisionDx-Melanoma's ability to predict low SLN positivity and high recurrence risk in melanoma patients. The study involved 2,799 patients across 29 U.S. centers, with low-risk patients avoiding SLNB showing 99.6% five-year RFS. The test also stratified recurrence risk in early-stage, transected melanomas, supporting tailored surveillance. Castle Biosciences is a Nasdaq-listed company (CSTL).

prnewswire.com